Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Spritam, you must consult a qualified healthcare professional.
| 500 mg/1 | TABLET, FOR SUSPENSION | ORAL | 43485-102 |
Detailed information about Spritam
Levetiracetam is a second-generation antiepileptic drug (AED) used to treat various seizure types. It is known for its unique mechanism of action and minimal drug-drug interactions compared to older anticonvulsants.
For adults (16 years and older) with partial-onset, myoclonic, or primary generalized tonic-clonic seizures, the standard starting dose of immediate-release levetiracetam is 500 mg taken twice daily (1000 mg total per day). Depending on how the patient responds and tolerates the medication, a healthcare provider may increase the dose by 1000 mg per day every two weeks. The maximum recommended daily dose is typically 3000 mg per day, divided into two doses. For extended-release formulations, the starting dose is usually 1000 mg once daily, with adjustments made in 1000 mg increments every two weeks up to a maximum of 3000 mg once daily.
Levetiracetam is approved for use in children, but the dosage is strictly based on weight (mg/kg) and age.
Parents must use a calibrated measuring device for the oral solution to ensure the child receives the exact prescribed amount. Household spoons are not accurate and should never be used.
Because levetiracetam is primarily cleared by the kidneys, dosage adjustments are mandatory for patients with impaired renal function. Healthcare providers use the Creatinine Clearance (CrCl) rate to determine the appropriate dose. For patients with severe renal impairment (CrCl <30 mL/min), the dose may be reduced by 50% or more. Patients on hemodialysis require a supplemental dose after each dialysis session because the procedure removes the drug from the bloodstream.
No dosage adjustment is generally needed for patients with mild to moderate liver disease. However, in patients with severe hepatic impairment, the healthcare provider may check renal function and adjust the dose accordingly, as liver failure can sometimes affect kidney performance.
Dosage selection for elderly patients should be cautious, usually starting at the low end of the dosing range. This is primarily because older adults are more likely to have decreased renal function and may be more sensitive to the sedative side effects of the medication.
Levetiracetam should be taken exactly as prescribed by your doctor. It can be taken with or without food, but it is best to take it at the same times each day to maintain a steady level of the drug in your system.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one. Frequent missed doses can trigger "breakthrough seizures," which can be dangerous.
Symptoms of a levetiracetam overdose may include extreme drowsiness, agitation, aggression, decreased consciousness, or difficulty breathing. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. There is no specific antidote for levetiracetam; treatment in a hospital setting involves supportive care and potentially hemodialysis to remove the drug from the system.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can cause status epilepticus.
Most patients tolerate levetiracetam well, but side effects are common, especially during the first few weeks of treatment as the body adjusts. The most frequently reported side effects include:
Levetiracetam is a powerful neurological medication that must be used with caution. Patients should never share this medication with others, even if they have similar symptoms. It is vital to maintain regular appointments with your neurologist to monitor the drug's efficacy and safety. Because the drug affects the central nervous system, patients should be aware of how it impacts their mental state and physical coordination.
No FDA black box warnings for Levetiracetam. However, as noted in the side effects section, it carries a standard class-wide warning for all anticonvulsants regarding the risk of suicidal ideation and behavior. Patients, caregivers, and families should be alert for the emergence or worsening of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm.
There is a risk of serious allergic reactions. If you experience hives, swelling of the lips or face, or difficulty breathing, seek emergency care. There have also been reports of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), a multi-organ hypersensitivity reaction that can be fatal.
There are no absolute drug-drug contraindications where levetiracetam must never be used with another agent, which is one of its primary advantages. However, it should not be used in patients who have had a previous severe allergic reaction to levetiracetam or any of its excipients.
An absolute contraindication is a condition where the medication must not be used under any circumstances because the risk clearly outweighs any possible benefit.
Relative contraindications are conditions where caution is required, and the drug should only be used if the benefits outweigh the risks.
Levetiracetam is frequently used during pregnancy because it is generally considered to have a lower risk of causing major birth defects compared to older drugs like valproate. However, it is not without risk.
Levetiracetam's primary mechanism involves binding to the Synaptic Vesicle Protein 2A (SV2A). This protein is located on the membranes of presynaptic vesicles, which are the "storage sacs" for neurotransmitters in the brain. By binding to SV2A, levetiracetam is thought to modulate the release of neurotransmitters. Specifically, it appears to decrease the release of excitatory neurotransmitters like glutamate during periods of high-frequency neuronal activity (seizures) without affecting normal, low-frequency communication between neurons. It also inhibits N-type calcium channels and modulates intraneuronal calcium release, which further stabilizes neuronal excitability.
Levetiracetam provides a broad spectrum of antiepileptic activity. It does not show affinity for conventional receptors like GABA, glycine, or NMDA. Its effect is dose-dependent, and it typically reaches a steady state in the blood within 48 hours of starting a consistent twice-daily regimen. There is no evidence of patients developing a tolerance to its antiepileptic effects over time.
| Parameter | Value |
Common questions about Spritam
Levetiracetam is primarily used to treat various types of seizures in patients with epilepsy. It is FDA-approved for partial-onset seizures in adults and children as young as one month old. Additionally, it is used as an add-on treatment for myoclonic seizures in people with juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures. Some doctors may also use it off-label for status epilepticus or to prevent seizures after a head injury. It works by stabilizing electrical activity in the brain through a unique protein-binding mechanism.
The most common side effects reported by patients taking levetiracetam include sleepiness, weakness, dizziness, and infection (like the common cold). Many patients also experience behavioral changes such as irritability, mood swings, or anxiety, which are often referred to as 'Keppra-rage' in patient communities. These side effects are usually most intense during the first few weeks of treatment and may subside as the body adjusts. However, if behavioral changes become severe or include thoughts of self-harm, you must contact your doctor immediately. It is important to monitor your reactions closely when starting the medication.
It is generally recommended to avoid or significantly limit alcohol consumption while taking levetiracetam. Alcohol can worsen the side effects of the medication, particularly drowsiness, dizziness, and impaired coordination, which increases the risk of accidents. More importantly, alcohol itself can trigger seizures or lower the seizure threshold, making your medication less effective. Even small amounts of alcohol can interfere with the stability of your treatment. Always discuss your lifestyle and alcohol use with your neurologist to understand your specific risks.
Levetiracetam is considered one of the safer options for managing seizures during pregnancy compared to older drugs like valproate. However, no medication is entirely without risk, and it should only be used if the benefit to the mother outweighs the potential risk to the fetus. Doctors often monitor blood levels more frequently during pregnancy because the body clears the drug faster, which could lead to a breakthrough seizure. Pregnant women are encouraged to join a pregnancy registry to help monitor the safety of the drug. Always consult your specialist if you are planning to become pregnant or find out you are pregnant while on this drug.
Levetiracetam is absorbed very quickly by the body, reaching peak levels in the bloodstream within about an hour of taking a dose. While the drug begins working on the brain almost immediately, it may take several days of consistent dosing to reach a 'steady state' where the level of medicine in your blood remains constant. Most patients see a reduction in seizure frequency within the first week or two of starting treatment. Your doctor will likely start you on a low dose and gradually increase it to find the most effective level for you. Patience is key during this titration period.
No, you should never stop taking levetiracetam suddenly unless specifically instructed by your doctor in an emergency. Abruptly stopping an antiepileptic medication can cause 'rebound seizures,' which may be more frequent or severe than your original seizures. It can also lead to status epilepticus, a continuous seizure state that is a medical emergency. If you need to switch medications or stop treatment, your doctor will provide a schedule to slowly decrease your dose over several weeks. This allows your brain to adjust safely to the change.
If you miss a dose of levetiracetam, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, you should skip the missed dose and simply take your next one at the regular time. Never take a double dose to make up for a missed one, as this can increase the risk of side effects like extreme drowsiness. Consistency is vital for seizure control, so try to take your medication at the same time every day. Using a pillbox or a phone alarm can help you stay on track with your regimen.
Weight gain is not a common side effect of levetiracetam; in fact, some patients report a decrease in appetite (anorexia) which can lead to slight weight loss. This makes it different from other seizure medications like valproate or gabapentin, which are frequently associated with weight gain. If you notice significant changes in your weight while taking this medication, it is worth discussing with your healthcare provider. They can help determine if the weight change is related to the drug or another underlying factor. Maintaining a balanced diet and regular exercise is always recommended.
One of the main benefits of levetiracetam is that it has very few interactions with other drugs because it is not processed by the liver's primary enzyme system. It can usually be taken safely with birth control pills, blood thinners, and most antibiotics. However, it can have additive effects with other drugs that cause sleepiness, such as opioids or sleep aids. You should always provide your doctor and pharmacist with a full list of all medications and supplements you are taking. This ensures that any potential interactions, however rare, can be identified early.
Yes, levetiracetam is available as a generic medication in several forms, including immediate-release tablets, extended-release tablets, and oral solutions. Generic versions are typically much more affordable than the brand-name version, Keppra, and are required by the FDA to have the same active ingredient and efficacy. Most insurance plans prefer the generic version. While most patients can switch between brand and generic without issues, some neurologists prefer that patients stay on the same manufacturer's version once they are stable. Discuss with your pharmacist if you have concerns about switching.
Other drugs with the same active ingredient (Levetiracetam)
While rare, some side effects are life-threatening and require immediate intervention:
> Warning: Stop taking Levetiracetam and call your doctor immediately if you experience any of these serious symptoms.
Long-term use of levetiracetam is generally considered safe, but patients should be monitored for persistent behavioral changes. Unlike some other AEDs, levetiracetam is not strongly associated with significant bone density loss (osteoporosis), but regular health check-ups are still advised. There is limited evidence regarding its long-term impact on cognitive function, though most studies suggest it is less cognitively impairing than older drugs like phenobarbital.
Currently, there are no specific FDA Black Box Warnings for levetiracetam. However, the FDA requires a general warning for all antiepileptic drugs regarding the increased risk of suicidal thoughts and behavior. This risk was identified in a pooled analysis of 199 placebo-controlled clinical trials, where the risk of suicidal behavior was approximately twice that of the placebo group (0.43% vs 0.24%).
Report any unusual symptoms to your healthcare provider. Keeping a side-effect diary can help your doctor determine if the medication is the cause of your symptoms and whether a dose adjustment is necessary.
Levetiracetam can cause significant psychiatric symptoms. In clinical trials, approximately 13% of adult patients and 38% of pediatric patients experienced behavioral adverse events. These include aggression, agitation, anger, anxiety, apathy, depression, hostility, and irritability. In some cases, these symptoms were severe enough to require discontinuation of the drug.
Antiepileptic drugs, including levetiracetam, should be withdrawn gradually to minimize the potential of increased seizure frequency and status epilepticus. If the drug must be discontinued due to a serious adverse event, the transition to another AED should be managed closely by a specialist.
While rare, levetiracetam can cause significant decreases in red blood cell counts, white blood cell counts, and platelets. Patients who develop unexplained fever, sore throat, or easy bruising should have a complete blood count (CBC) performed.
While routine blood level monitoring of levetiracetam is not usually necessary (unlike phenytoin or carbamazepine), it may be useful in certain situations, such as during pregnancy, in patients with kidney failure, or when checking for medication adherence. Periodic monitoring of renal function (kidney tests) is recommended, especially in elderly patients. Behavioral monitoring is the most critical aspect of follow-up care for this specific drug.
Levetiracetam may cause somnolence (sleepiness) and dizziness. Patients should not drive, operate heavy machinery, or engage in potentially hazardous activities until they are reasonably certain that the medication does not affect their ability to perform these tasks safely. Many jurisdictions have specific laws regarding driving for individuals with a history of seizures; consult your doctor and local regulations.
Alcohol can increase the sedative effects of levetiracetam, leading to extreme drowsiness and impaired coordination. Furthermore, alcohol consumption itself can lower the seizure threshold, making the medication less effective at preventing seizures. It is generally advised to avoid or strictly limit alcohol while taking this medication.
Never stop taking levetiracetam abruptly. Sudden cessation can trigger "rebound seizures" or status epilepticus, a life-threatening condition where seizures do not stop. If you need to stop the medication, your doctor will provide a tapering schedule, usually reducing the dose gradually over several weeks.
> Important: Discuss all your medical conditions, including any history of depression or kidney disease, with your healthcare provider before starting Levetiracetam.
Levetiracetam does not have significant interactions with specific foods. Unlike some other medications, it does not interact with grapefruit juice. It can be taken with or without food. However, maintaining a consistent routine (always taking it with food or always without) can help keep blood levels stable.
Levetiracetam is not known to interfere with most common laboratory tests. However, it does not show up on standard urine drug screens for drugs of abuse. If a specific blood level is needed, a specialized assay must be requested from the laboratory.
Most interactions involving levetiracetam are pharmacodynamic, meaning the drugs have additive effects on the body (such as increased sedation), rather than pharmacokinetic (where one drug changes the blood level of another). Because levetiracetam avoids the CYP450 liver enzyme system and has low protein binding, it is often the preferred choice for patients on complex medication regimens for HIV, cancer, or organ transplants.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even "natural" products can interfere with seizure control.
There is no known cross-sensitivity between levetiracetam and other common antiepileptic classes like sulfonamides (zonisamide), hydantoins (phenytoin), or carboxamides (carbamazepine). However, patients who are sensitive to pyrrolidine derivatives should be monitored closely. Always inform your doctor of any previous drug allergies to ensure a safe prescribing choice.
> Important: Your healthcare provider will evaluate your complete medical history, including your mental health history and kidney function, before prescribing Levetiracetam.
Levetiracetam passes into breast milk. While many infants do not experience adverse effects, there is a risk of drowsiness, irritability, or poor weight gain in the nursing infant. The decision to breastfeed should be made by weighing the benefits of breastfeeding against the potential risks of drug exposure. If breastfeeding, the infant should be monitored closely for excessive sleepiness.
Levetiracetam is approved for infants as young as 1 month old for partial-onset seizures. It is generally well-tolerated in children, but the risk of behavioral side effects (irritability, aggression) is significantly higher in the pediatric population than in adults. Parents must be vigilant in monitoring their child's mood and behavior. It does not appear to affect growth or bone development significantly.
In patients over 65, the primary concern is age-related decline in kidney function. Since levetiracetam is cleared by the kidneys, the dose must be carefully adjusted based on the patient's creatinine clearance. Elderly patients are also more susceptible to dizziness and somnolence, which can increase the risk of falls and fractures.
For patients with a Creatinine Clearance (CrCl) of 50-80 mL/min, the dose is typically 500-1500 mg every 12 hours. For CrCl 30-50 mL/min, the dose is 250-750 mg every 12 hours. For CrCl <30 mL/min, the dose is 250-500 mg every 12 hours. Patients on dialysis should receive a supplemental dose of 250-500 mg after each session.
No adjustment is needed for mild to moderate hepatic impairment. In severe hepatic impairment (Child-Pugh C), renal clearance may be reduced, so a lower starting dose and careful monitoring are advised.
> Important: Special populations require individualized medical assessment and frequent monitoring by a specialist.
|---|---|
| Bioavailability | ~100% |
| Protein Binding | <10% |
| Half-life | 7–8 hours (Adults) |
| Tmax | 1 hour (Fasting) |
| Metabolism | Enzymatic hydrolysis (Non-CYP) |
| Excretion | Renal (66% unchanged) |
Levetiracetam is classified as a Pyrrolidine Anticonvulsant. It is often grouped with newer-generation antiepileptic drugs. A related medication in the same class is Brivaracetam (Briviact), which also binds to SV2A but with much higher affinity.